Towards practical cognitive assessment for detection of early dementia: a 30-minute computerized battery discriminates as well as longer testing.

Early detection of cognitive decline may lead to more effective treatment. Clinical cognitive assessment is essential for early detection, but must be brief with easily interpretable results. The present study defines and evaluates a 30-minute cognitive battery consisting of a subset of tests that comprise a longer computerized battery recently validated in detecting mild cognitive impairment (MCI). Participants were from three tertiary care memory clinics and an assisted living facility (final group: N=161) with consensus diagnoses of cognitively healthy, MCI, or mild dementia. A comprehensive NeuroTrax battery evaluated memory, executive function, visual spatial perception, verbal function, information processing speed, and motor skills. Validity of a single summary measure ('MCI Score') designed for dementia detection and built exclusively from tests of memory, executive function, and visual spatial perception was evaluated with receiver operating characteristic (ROC) analysis. Discriminant validity (area under the curve: AUC) was at least as large for the 6-parameter MCI Score as for a 20-parameter score necessitating administration of the entire battery. Further, the MCI Score had a larger AUC with reduced variance relative to its constituent parameters. AUC for distinguishing dementia was 0.886; AUC for distinguishing cognitively healthy was 0.823. Finally, the MCI Score discriminated among all three diagnostic groups (ANOVA; F[2,150]=52.54, p<0.001). Hence a reduced NeuroTrax battery (30 minutes) with MCI Score is a useful clinical tool for summarizing cognitive data relevant to early dementia detection.

[1]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[2]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[3]  J. Cauraugh,et al.  Speed-accuracy tradeoff during response preparation. , 1990, Research quarterly for exercise and sport.

[4]  Colin M. Macleod.  Half a century of research on the Stroop effect: an integrative review. , 1991, Psychological bulletin.

[5]  R. Green,et al.  Screening for cognitive impairment in older individuals. Validation study of a computer-based test. , 1994, Archives of neurology.

[6]  H. Creasey,et al.  Age at onset and pattern of neuropsychological impairment in mild early-stage Alzheimer disease. A study of a community-based population. , 1996, Archives of neurology.

[7]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[8]  G. Ratcliff,et al.  Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented , 2000, Neurology.

[9]  D Commenges,et al.  A cognitive screening battery for dementia in the elderly. , 2000, Journal of clinical epidemiology.

[10]  E. Tangalos,et al.  CME Practice parameter: , 2022 .

[11]  J. Touchon,et al.  Classification criteria for mild cognitive impairment , 2001, Neurology.

[12]  J. Price,et al.  Mild cognitive impairment represents early-stage Alzheimer disease. , 2001, Archives of neurology.

[13]  L. Beckett,et al.  Annual Incidence of Alzheimer Disease in the United States Projected to the Years 2000 Through 2050 , 2001, Alzheimer disease and associated disorders.

[14]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[15]  N. Foster,et al.  Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. , 2001, Archives of neurology.

[16]  P. Maruff,et al.  Mild cognitive impairment can be detected by multiple assessments in a single day , 2002, Neurology.

[17]  J. Schneider,et al.  Cognitive activity and incident AD in a population-based sample of older persons , 2002, Neurology.

[18]  D. A. Bennett,et al.  Natural history of mild cognitive impairment in older persons , 2002, Neurology.

[19]  L. Thal,et al.  Alzheimer’s disease can be accurately diagnosed in very mildly impaired individuals , 2002, Neurology.

[20]  M. Angermeyer,et al.  Mild cognitive impairment 1 – a review of prevalence, incidence and outcome according to current approaches , 2002, Acta psychiatrica Scandinavica.

[21]  K. Ritchie,et al.  The detection of mild cognitive impairment in the general practice setting , 2003, Aging & mental health.

[22]  M. Pepe.  The Statistical Evaluation of Medical Tests for Classification and Prediction , 2003 .

[23]  Ronald C. Petersen,et al.  Mild cognitive impairment clinical trials , 2003, Nature Reviews Drug Discovery.

[24]  Kenneth Rockwood,et al.  Variations in case definition affect prevalence but not outcomes of mild cognitive impairment , 2003, Neurology.

[25]  V. Solfrizzi,et al.  The role of diet in cognitive decline , 2003, Journal of Neural Transmission.

[26]  Andrew D. Blackwell,et al.  Detecting Dementia: Novel Neuropsychological Markers of Preclinical Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[27]  R Brookmeyer,et al.  Visual memory predicts Alzheimer’s disease more than a decade before diagnosis , 2003, Neurology.

[28]  Steven Potkin,et al.  Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. , 2003, Archives of neurology.

[29]  D. Loewenstein,et al.  Mild cognitive impairment , 2003, Neurology.

[30]  D. Bennett.  Update on mild cognitive impairment , 2003, Current neurology and neuroscience reports.

[31]  Charles J Duffy,et al.  A visuospatial variant of mild cognitive impairment , 2003, Neurology.

[32]  Avraham Schweiger,et al.  Validity of a novel computerized cognitive battery for mild cognitive impairment , 2003, BMC geriatrics.

[33]  J. Bischkopf,et al.  Mild cognitive impairment 1 : prevalence and predictive validity according to current approaches , 2003, Acta neurologica Scandinavica.

[34]  Mild cognitive impairment as a useful clinical construct , 2003 .

[35]  C. Holmes,et al.  Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.